secwatch.observer — SEC 8-K summary
======================================

Issuer:     LENSAR, Inc. (LNSR)
CIK:        0001320350
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001564590-22-018696
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LENSAR Q1 2022 revenue $9.3M (+33% YoY); net loss $6.7M; ALLY 510(k) under FDA review
--------------------------------------------------------------------------------

- Total revenue $9.3M, up 33% from $7.0M in Q1 2021; 89% from recurring sources.
- Procedure volume 38,901, up 38% YoY; product, lease, and service revenue all increased.
- Net loss $6.7M ($0.67 per share) vs $5.2M ($0.56) in Q1 2021; R&D expense rose 74% to $4.8M due to ALLY development.
- FDA accepted 510(k) for ALLY Adaptive Cataract Treatment System; launch anticipated in 2022 if cleared.
- Adjusted EBITDA was ($4.2)M vs ($2.2)M in Q1 2021; stock-based comp $1.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022018696/0001564590-22-018696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1320350/000156459022018696/lnsr-8k_20220509.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-018696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer